Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Predictors and management of intravenous immunoglobulin-resistant Kawasaki disease

  • Song, Min Seob (Department of Pediatrics, Inje University Haeundae Paik Hospital, Inje University College of Medicine)
  • Received : 2019.02.13
  • Accepted : 2019.03.13
  • Published : 2019.04.15
Download PDF
⟨ Previous Next ⟩

Abstract

Kawasaki disease (KD) is a systemic vasculitis that mainly affects younger children. Intravenous immunoglobulin (IVIG) resistant cases are at increasing risk for coronary artery complications. The strategy on prediction of potential nonresponders and treatment of IVIG-resistant patients is now controversial. In this review the definition and predictors of IVIG-resistant KD and current evidence to guide management are discussed.

Keywords

References

  1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 1967;16:178-222.
  2. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 2017;135:e927-99. https://doi.org/10.1161/CIR.0000000000000484
  3. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998;17:1144-8. https://doi.org/10.1097/00006454-199812000-00009
  4. Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000;105:E78. https://doi.org/10.1542/peds.105.6.e78
  5. Tremoulet AH, Best BM, Song S, Wang S, Corinaldesi E, Eichenfield JR, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 2008;153:117-21. https://doi.org/10.1016/j.jpeds.2007.12.021
  6. Dionne A, Le CK, Poupart S, Autmizguine J, Meloche-Dumas L, Turgeon J, et al. Profile of resistance to IVIG treatment in patients with Kawasaki disease and concomitant infection. PLoS One 2018;13:e0206001. https://doi.org/10.1371/journal.pone.0206001
  7. Kim HK, Kim HG, Cho SJ, Hong YM, Sohn S, Yoo ES, et al. Clinical characteristics of hemophagocytic lymphohistiocytosis related to Kawasaki disease. Pediatr Hematol Oncol 2011;28:230-6. https://doi.org/10.3109/08880018.2010.526685
  8. Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006;113:2606-12. https://doi.org/10.1161/CIRCULATIONAHA.105.592865
  9. Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006;149:237-40. https://doi.org/10.1016/j.jpeds.2006.03.050
  10. Sleeper LA, Minich LL, McCrindle BM, Li JS, Mason W, Colan SD, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr 2011;158:831-5. https://doi.org/10.1016/j.jpeds.2010.10.031
  11. Davies S, Sutton N, Blackstock S, Gormley S, Hoggart CJ, Levin M, et al. Predicting IVIG resistance in UK Kawasaki disease. Arch Dis Child 2015;100:366-8. https://doi.org/10.1136/archdischild-2014-307397
  12. Baek JY, Song MS. Meta-analysis of factors predicting resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. Korean J Pediatr 2016;59:80-90. https://doi.org/10.3345/kjp.2016.59.2.80
  13. Li X, Chen Y, Tang Y, Ding Y, Xu Q, Sun L, et al. Predictors of intravenous immunoglobulin-resistant Kawasaki disease in children: a meta-analysis of 4442 cases. Eur J Pediatr 2018;177:1279-92. https://doi.org/10.1007/s00431-018-3182-2
  14. Dionne A, Dahdah N. A Decade of NT-proBNP in Acute Kawasaki disease, from physiological response to clinical relevance. Children (Basel) 2018;2018;5:141. https://doi.org/10.3390/children5100141
  15. Yoshimura K, Kimata T, Mine K, Uchiyama T, Tsuji S, Kaneko K. N-terminal pro-brain natriuretic peptide and risk of coronary artery lesions and resistance to intravenous immunoglobulin in Kawasaki disease. J Pediatr 2013;162:1205-9. https://doi.org/10.1016/j.jpeds.2012.11.026
  16. Kim SY, Han MY, Cha SH, Jeon YB. N-terminal pro-brain natriuretic peptide (NT proBNP) as a predictive indicator of initial intravenous immunoglobulin treatment failure in children with Kawasaki disease: a retrospective study. Pediatr Cardiol 2013;34:1837-43. https://doi.org/10.1007/s00246-013-0724-2
  17. Kim HK, Oh J, Hong YM, Sohn S. Parameters to guide retreatment after initial intravenous immunoglobulin therapy in Kawasaki disease. Korean Circ J 2011;41:379-84. https://doi.org/10.4070/kcj.2011.41.7.379
  18. Seo YM, Kang HM, Lee SC, Yu JW, Kil HR, Rhim JW, et al. Clinical implications in laboratory parameter values in acute Kawasaki disease for early diagnosis and proper treatment. Korean J Pediatr 2018;61:160-6. https://doi.org/10.3345/kjp.2018.61.5.160
  19. Chbeir D, Gaschignard J, Bonnefoy R, Beyler C, Melki I, Faye A, et al. Kawasaki disease: abnormal initial echocardiogram is associated with resistance to IV Ig and development of coronary artery lesions. Pediatr Rheumatol Online J 2018;16:48. https://doi.org/10.1186/s12969-018-0264-7
  20. Friedman KG, Gauvreau K, Hamaoka-Okamoto A, Tang A, Berry E, Tremoulet AH, et al. Coronary artery aneurysms in Kawasaki disease: risk factors for progressive disease and adverse cardiac events in the US population. J Am Heart Assoc 2016;5:e003289.
  21. Son MBF, Gauvreau K, Kim S, Tang A, Dedeoglu F, Fulton DR, et al. Predicting coronary artery aneurysms in Kawasaki disease at a North American Center: an assessment of baseline z scores. J Am Heart Assoc 2017;6:e005378. https://doi.org/10.1161/JAHA.116.005378
  22. Yoon KL. Update of genetic susceptibility in patients with Kawasaki disease. Korean J Pediatr 2015;58:84-8. https://doi.org/10.3345/kjp.2015.58.3.84
  23. Sundel RP, Burns JC, Baker A, Beiser AS, Newburger JW. Gamma globulin re-treatment in Kawasaki disease. J Pediatr 1993;123:657-9. https://doi.org/10.1016/S0022-3476(05)80972-2
  24. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979;63:175-9.
  25. Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996;128:146-9. https://doi.org/10.1016/S0022-3476(96)70447-X
  26. Wardle AJ, Connolly GM, Seager MJ, Tulloh RM. Corticosteroids for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2017;1:CD011188.
  27. Kibata T, Suzuki Y, Hasegawa S, Matsushige T, Kusuda T, Hoshide M, et al. Coronary artery lesions and the increasing incidence of Kawasaki disease resistant to initial immunoglobulin. Int J Cardiol 2016;214:209-15. https://doi.org/10.1016/j.ijcard.2016.03.017
  28. Chen S, Dong Y, Kiuchi MG, Wang J, Li R, Ling Z, et al. Coronary artery complication in Kawasaki disease and the importance of early intervention: a systematic review and meta-analysis. JAMA Pediatr 2016;170:1156-63. https://doi.org/10.1001/jamapediatrics.2016.2055
  29. Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012;379:1613-20. https://doi.org/10.1016/S0140-6736(11)61930-2
  30. Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, et al. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study. Lancet Child Adolesc Health 2018;2:855-62. https://doi.org/10.1016/S2352-4642(18)30293-1
  31. Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005;146:662-7. https://doi.org/10.1016/j.jpeds.2004.12.022
  32. Song MS, Lee SB, Sohn S, Oh JH, Yoon KL, Han JW, et al. Infliximab treatment for refractory kawasaki disease in Korean children. Korean Circ J 2010;40:334-8. https://doi.org/10.4070/kcj.2010.40.7.334
  33. Son MB, Gauvreau K, Burns JC, Corinaldesi E, Tremoulet AH, Watson VE, et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr 2011;158:644-9. https://doi.org/10.1016/j.jpeds.2010.10.012
  34. Masuda H, Kobayashi T, Hachiya A, Nakashima Y, Shimizu H, Nozawa T, et al. Infliximab for the treatment of refractory Kawasaki disease: a nationwide survey in Japan. J Pediatr 2018;195:115-20. https://doi.org/10.1016/j.jpeds.2017.10.013
  35. Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebocontrolled trial. Lancet 2014;383:1731-8. https://doi.org/10.1016/S0140-6736(13)62298-9
  36. Hur G, Song MS, Sohn S, Lee HD, Kim GB, Cho HJ, et al. Infliximab treatment for intravenous immunoglobulin-resistant Kawasaki disease: a multicenter study in Korea. Korean Circ J 2019;49:183-91. https://doi.org/10.4070/kcj.2018.0214
  37. Choueiter NF, Olson AK, Shen DD, Portman MA. Prospective openlabel trial of etanercept as adjunctive therapy for Kawasaki disease. J Pediatr 2010;157:960-6. https://doi.org/10.1016/j.jpeds.2010.06.014
  38. Suzuki H, Terai M, Hamada H, Honda T, Suenaga T, Takeuchi T, et al. Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr Infect Dis J 2011;30:871-6. https://doi.org/10.1097/INF.0b013e318220c3cf
  39. Tremoulet AH, Pancoast P, Franco A, Bujold M, Shimizu C, Onouchi Y, et al. Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2012;161:506-12. https://doi.org/10.1016/j.jpeds.2012.02.048
  40. Jang H, Kim KY, Kim DS. Clinical outcomes of low-dose methotrexate therapy as a second-line drug for intravenous immunoglobulinresistant Kawasaki disease. Yonsei Med J 2018;59:113-8. https://doi.org/10.3349/ymj.2018.59.1.113
  41. Shafferman A, Birmingham JD, Cron RQ. High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report. Pediatr Rheumatol Online J 2014;12:26. https://doi.org/10.1186/1546-0096-12-26
  42. Kone-Paut I, Cimaz R, Herberg J, Bates O, Carbasse A, Saulnier JP, et al. The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: a retrospective cases series. Autoimmun Rev 2018;17:768-74. https://doi.org/10.1016/j.autrev.2018.01.024
  43. Hokosaki T, Mori M, Nishizawa T, Nakamura T, Imagawa T, Iwamoto M, et al. Long-term efficacy of plasma exchange treatment for refractory Kawasaki disease. Pediatr Int 2012;54:99-103. https://doi.org/10.1111/j.1442-200X.2011.03487.x